Desmopressin: A nontransfusional form of treatment for congenital and acquired bleeding disorders

Research output: Contribution to journalArticlepeer-review

Abstract

Desmopressin (1-deamino-8-D-arginine vasopressin, abbreviated DDAVP) is a synthetic analogue of the antidiuretic hormone L-arginine vasopressin. Because it can rise circulating levels of factor VIII coagulant activity (FVIII) and von Willebrand factor and shorten the prolonged bleeding time, DDAVP is established as a nontransfusional form of treatment for mild and moderate hemophilia and von Willebrand disease. Recently, DDAVP has also been purported to be useful for shortening the prolonged skin bleeding times that occur with uremia, cirrhosis, and platelet dysfunctions of various etiologies. Finally, there is evidence from controlled clinical trials that DDAVP can reduce blood loss and transfusion requirements for hemostatically normal individuals undergoing spinal fusion surgery and for patients undergoing cardiopulmonary bypass surgery. The purpose of this report is to review the therapeutic applications of DDAVP in congenital and acquired bleeding disorders and to discuss areas in which further basic and clinical research is needed.

Original languageEnglish
Pages (from-to)1449-1455
Number of pages7
JournalBlood
Volume72
Issue number5
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Desmopressin: A nontransfusional form of treatment for congenital and acquired bleeding disorders'. Together they form a unique fingerprint.

Cite this